AMLX-Advisory Committee Meeting

This is the date that the Advisory Committee will reconvene to discuss new additions to studies presented in March of this year.  An Ad Com is a RUMOR FUELER, because while they do vote on whether the drug is worth presenting to the FDA, the FDA is not binded to the decision the Ad Com makes.  They can, and have in the past, go the complete opposite direction.  So a positive Ad Com can be quite a rumor fueler, and not just an “Event.”

Link to the PR below:

https://www.amylyx.com/media/amylyx-pharmaceuticals-announces-fda-plan-to-reconvene-advisory-committee-to-review-amx0035-nda-for-the-treatment-of-als-on-september-7-2022